Aprea Therapeutics
Latest round
- Series C
Last raised
- Feb 2019
Total raised
- $112M
Investors
- 8
About Aprea Therapeutics
Founded in 2003 and headquartered in Boston, US, Aprea Therapeutics specializes in cancer therapeutics. The company’s CEO is Oren Gilad, and it was founded by Vladimir Bykov.Aprea Therapeutics specializes in developing innovative DNA Damage Response (DDR) targeted cancer therapeutics aimed at addressing specific genetic mutations associated with various cancer types. The company's core product offerings include small molecule inhibitors designed to enhance the efficacy of cancer treatments while minimizing toxicity to healthy tissues. These therapeutics are crafted to widen the therapeutic window, focusing on the precise matching of treatments to patients based on their unique cancer profiles. Aprea’s product pipeline targets multiple genetic mutations to improve treatment outcomes, thereby catering to a diverse client base that includes healthcare providers and oncology specialists in regions such as North America and Europe.In 2023, Aprea Therapeutics reported revenue of USD 583,231. The company also faced an EBITDA loss of USD 15,464,911 for the same year. Aprea generates revenue through collaborations and partnerships with healthcare institutions and pharmaceutical companies, focusing on B2B transactions. The structure of these partnerships may involve licensing agreements and joint ventures, enabling the company to leverage external expertise while advancing its therapeutic pipeline. The company is also looking to expand its market reach, particularly in North America and Europe, by launching new products tailored to specific genetic mutations in cancer.
Who invested in Aprea Therapeutics
8 investors across 3 rounds
See all investors in Aprea Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Aprea Therapeutics
Who invested in Aprea Therapeutics?
Aprea Therapeutics has 8 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Aprea Therapeutics raised?
Aprea Therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Aprea Therapeutics last raise money?
Aprea Therapeutics's most recent round on record is a Series C, in Feb 2019.
What does Aprea Therapeutics do?
Founded in 2003 and headquartered in Boston, US, Aprea Therapeutics specializes in cancer therapeutics.
Where is Aprea Therapeutics headquartered?
Aprea Therapeutics is headquartered in Boston, US.
Which VCs invest in companies like Aprea Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Aprea Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Aprea Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.